ODAC Asks Sandoz If Biosimilar Price Is Right
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee member wants to know if approval of filgrastim would lead to lower prices; Sandoz responds that price may be at parity, but cost to patients and payers would be lower.